P
Premas Biotech
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-Crypt™ the difficult to express proteins expression platform, Premas' leading technologies include Axtex-4D™: an ex-vivo tissueoid generation platform and C-Qwence™: a fully human naive India based scFv antibody library.
Country/Area ：India
Company Email ：hr@premasbiotech.com
Industry ：Manufacturing GeneralManufacturingApps
Company address ：13 High Field Ln, Madison, Connecticut, 06443, United States
Company website ：*****
Company phone ：+91 1244546600
Established ：2005
Company Revenue ：$31,520,000
Number of employees ：145
SIC Code ：28283
NAICS Code ：54541
Company News
Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern
Dec 1, 2021
GURUGRAM, India--(BUSINESS WIRE)-- #COVID19--Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern.
Dec 1, 2021
Premas Biotech secures licensing deal for commercializing its vaccine technology in IndiaAug 3, 2021
Aug 3, 2021Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In IndiaJul 21, 2021
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc. read more
Jul 21, 2021Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single DoseMar 19, 2021
GURUGRAM, India--(BUSINESS WIRE)-- #Antibodies--Premas Biotech and Oramed announce Oral COVID-19 vaccine candidate that produces Antibodies after a single dose.
Mar 19, 2021Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept ResultsAug 27, 2020
Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice
Aug 27, 2020Business Info
CIN ：U24232HR2005PTC035932
Registered State ：Haryana
Registrar Of Companies ：RoC-Delhi
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Private
Company Status ：Active
Registered Office Address ：PLOT NO. 77, SECTOR 4 IMT MANESAR HR IN 122050
Authorized Cap ：220000000.00
Paidup Capital ：219938830.00
Web Summary
Q1: What is the address of Premas Biotech's headquarters?
A1: The address of Premas Biotech's headquarters in the United States is 13 High Field Lane, Madison, CT 06443. Additionally, they have offices in India located at Plot 77, Sector 4, IMT Manesar, Gurugram 122050, and Plot 79B80B, Sector 5, IMT Manesar.
Q2: What is the primary focus of Premas Biotech's services?
A2: The primary focus of Premas Biotech's services is to provide integrated solutions for protein expression, purification, and formulation. They offer a range of services including scouting, cell line development, process development, scaleup and manufacturing, analytical development, and functional assays.
Q3: What is the purpose of Premas Biotech's Axtex4D technology?
A3: The Axtex4D technology is a proprietary platform developed by Premas Biotech to optimize protein expression. It allows for rapid screening of 2000+ data points across four host expression systems (bacteria, yeast, and mammalian cells) to identify key parameters that enhance protein expression.
Q4: What types of proteins are challenging to express and purify?
A4: Difficulttoexpress proteins, such as membraneassociated proteins with high numbers of cysteine residues and proline residues, pose significant challenges in producing soluble expression and subsequent purification. These proteins are also susceptible to degradation and aggregation, making protein stability screening crucial.
Q5: What is the purpose of Premas Biotech's 48well plate formulation study?
A5: The 48well plate formulation study is a method developed by Premas Biotech to optimize protein formulations, including buffers, additives, stabilizers, excipients, etc. This study aims to stabilize proteins against physicochemical degradation and aggregation over the desired shelf life.
Q6: What are some of the key factors that influence protein stability?
A6: Factors such as temperature, pH, buffer composition, salt, metalions, cosolvents, preservatives, surfactants, protein concentration, and freezethaw cycles significantly impact protein stability in a solution.
Q7: What is Premas Biotech's approach to delivering proteins for various applications?
A7: Premas Biotech has developed a range of technologies and services to deliver proteins for various applications, including vaccine development, therapeutics, and other industries. They offer rapid expression optimization platforms, purification screens, formulation studies, and analytical development and functional assays.
Q8: How can customers contact Premas Biotech?
A8: Customers can contact Premas Biotech through their website or by reaching out to them directly via phone, email, or inperson at one of their offices. They also offer a collaboration opportunity for interested parties to discuss potential projects or partnerships.
A1: The address of Premas Biotech's headquarters in the United States is 13 High Field Lane, Madison, CT 06443. Additionally, they have offices in India located at Plot 77, Sector 4, IMT Manesar, Gurugram 122050, and Plot 79B80B, Sector 5, IMT Manesar.
Q2: What is the primary focus of Premas Biotech's services?
A2: The primary focus of Premas Biotech's services is to provide integrated solutions for protein expression, purification, and formulation. They offer a range of services including scouting, cell line development, process development, scaleup and manufacturing, analytical development, and functional assays.
Q3: What is the purpose of Premas Biotech's Axtex4D technology?
A3: The Axtex4D technology is a proprietary platform developed by Premas Biotech to optimize protein expression. It allows for rapid screening of 2000+ data points across four host expression systems (bacteria, yeast, and mammalian cells) to identify key parameters that enhance protein expression.
Q4: What types of proteins are challenging to express and purify?
A4: Difficulttoexpress proteins, such as membraneassociated proteins with high numbers of cysteine residues and proline residues, pose significant challenges in producing soluble expression and subsequent purification. These proteins are also susceptible to degradation and aggregation, making protein stability screening crucial.
Q5: What is the purpose of Premas Biotech's 48well plate formulation study?
A5: The 48well plate formulation study is a method developed by Premas Biotech to optimize protein formulations, including buffers, additives, stabilizers, excipients, etc. This study aims to stabilize proteins against physicochemical degradation and aggregation over the desired shelf life.
Q6: What are some of the key factors that influence protein stability?
A6: Factors such as temperature, pH, buffer composition, salt, metalions, cosolvents, preservatives, surfactants, protein concentration, and freezethaw cycles significantly impact protein stability in a solution.
Q7: What is Premas Biotech's approach to delivering proteins for various applications?
A7: Premas Biotech has developed a range of technologies and services to deliver proteins for various applications, including vaccine development, therapeutics, and other industries. They offer rapid expression optimization platforms, purification screens, formulation studies, and analytical development and functional assays.
Q8: How can customers contact Premas Biotech?
A8: Customers can contact Premas Biotech through their website or by reaching out to them directly via phone, email, or inperson at one of their offices. They also offer a collaboration opportunity for interested parties to discuss potential projects or partnerships.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
